Anzeige
Mehr »
Dienstag, 30.09.2025 - Börsentäglich über 12.000 News
Seltene Ausgangslage: Unbekannter Kupfer-Explorer mit spekulativem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D6Y4 | ISIN: US38942Q2021 | Ticker-Symbol:
NASDAQ
29.09.25 | 22:00
3,090 US-Dollar
+1,31 % +0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALCIMEDICA INC Chart 1 Jahr
5-Tage-Chart
CALCIMEDICA INC 5-Tage-Chart

Aktuelle News zur CALCIMEDICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.08.CalciMedica, Inc. - 10-Q, Quarterly Report2
12.08.CalciMedica GAAP EPS of -$0.40 misses by $0.051
CALCIMEDICA Aktie jetzt für 0€ handeln
12.08.CalciMedica, Inc. - 8-K, Current Report1
12.08.CalciMedica, Inc.: CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates107Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting...
► Artikel lesen
11.07.Hedge Fund and Insider Trading News: Ken Griffin, Scott Bessent, Ray Dalio, Bill Ackman, Warren Buffett, Caxton Associates, Man Group, Calcimedica Inc (CALC), and More11
27.06.CalciMedica, Inc. - 8-K, Current Report2
24.06.CalciMedica, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
06.06.CalciMedica ernennt Baker Tilly nach Fusion zur neuen Wirtschaftsprüfungsgesellschaft10
06.06.CalciMedica, Inc. - 8-K, Current Report1
14.05.CalciMedica GAAP EPS of -$0.36 misses by $0.061
14.05.CalciMedica, Inc. - 8-K, Current Report1
14.05.CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates134Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at...
► Artikel lesen
27.03.CalciMedica, Inc.: CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates485Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis...
► Artikel lesen
13.11.24CalciMedica, Inc.: CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates194Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora in acute pancreatitis (AP); Company expects to be in a position...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1